Publications by authors named "P Mohacsi"
Article Synopsis
- The EUROMACS study aimed to explore how the annual number of LVAD implantations at a medical center affects postoperative outcomes and patient survival.
- It analyzed data from 4,802 patients across 35 centers, categorizing them based on whether the center performed 30 or fewer vs. more than 30 implants per year, focusing on 1-year survival rates and device-related complications.
- Findings indicated that while higher volume centers had patients with more severe conditions, there was no significant difference in 1-year survival; however, higher volume centers had more device-related adverse events, highlighting the need for consistent quality improvement across all centers.
Late right heart failure (RHF) is increasingly recognized in patients with long-term left ventricular assist device (LVAD) support and is associated with decreased survival and increased incidence of adverse events such as gastrointestinal bleeding and stroke. Progression of right ventricular (RV) dysfunction to clinical syndrome of late RHF in patients supported with LVAD is dependent on the severity of pre-existing RV dysfunction, persistent or worsening left- or right-sided valvular heart disease, pulmonary hypertension, inadequate or excessive left ventricular unloading, and/or progression of the underlying cardiac disease. RHF likely represents a continuum of risk with early presentation and progression to late RHF.
View Article and Find Full Text PDFArticle Synopsis
- Early right-sided heart failure (RHF) occurred in 22% of patients after receiving a left ventricular assist device (LVAD), but the best treatment for this condition remains unclear, leading to the exploration of levosimendan's effectiveness.
- The study evaluated 3,661 LVAD patients from the EUROMACS Registry, with 399 treated with levosimendan before surgery, showing that those patients had higher RHF scores and longer ICU stays, but no notable differences in RHF rates or mortality at 30 days and 1 year.
- The findings indicate that levosimendan did not significantly influence the risk of early RHF or death, suggesting the need for further research through multicenter trials for more
Aims: Continuous-flow left ventricular assist devices (CF-LVADs) have become a standard of care in end-stage heart failure. Limited data exist comparing outcomes of HeartMate3 (HM3) and HeartWare HVAD (HW). We aimed to compare midterm outcomes of these devices.
View Article and Find Full Text PDF